Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, Martin T, Suvannasankha A, De Braganca KC, Corsale C, Schecter JM, Varsos H, Deraedt W, Wang L, Vogel M, Roccia T, Xu X, Mistry P, Zudaire E, Akram M, Nesheiwat T, Pacaud L, Avivi I, San-Miguel J. Cohen AD, et al. Among authors: mateos mv. Blood. 2023 Jan 19;141(3):219-230. doi: 10.1182/blood.2022015526. Blood. 2023. PMID: 36095849 Free PMC article.
[Multiple myeloma].
García-Sanz R, Mateos MV, San Miguel JF. García-Sanz R, et al. Among authors: mateos mv. Med Clin (Barc). 2007 Jun 16;129(3):104-15. doi: 10.1157/13107365. Med Clin (Barc). 2007. PMID: 17594862 Review. Spanish.
Bortezomib in multiple myeloma.
Mateos MV, San Miguel JF. Mateos MV, et al. Best Pract Res Clin Haematol. 2007 Dec;20(4):701-15. doi: 10.1016/j.beha.2007.09.003. Best Pract Res Clin Haematol. 2007. PMID: 18070714 Review.
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, González Y, Bladé J, Lahuerta JJ, Orfao A, San-Miguel JF; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Paiva B, et al. Among authors: mateos mv. Blood. 2009 Nov 12;114(20):4369-72. doi: 10.1182/blood-2009-05-221689. Epub 2009 Sep 15. Blood. 2009. PMID: 19755674 Free article.
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.
Paiva B, Vidriales MB, Pérez JJ, Mateo G, Montalbán MA, Mateos MV, Bladé J, Lahuerta JJ, Orfao A, San Miguel JF; GEM (Grupo Español de MM) cooperative study group; PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Paiva B, et al. Among authors: mateos mv. Haematologica. 2009 Nov;94(11):1599-602. doi: 10.3324/haematol.2009.009100. Haematologica. 2009. PMID: 19880781 Free PMC article.
Risk stratification in the era of novel therapies.
San-Miguel J, Mateos MV, Gutierrez NC. San-Miguel J, et al. Among authors: mateos mv. Cancer J. 2009 Nov-Dec;15(6):457-64. doi: 10.1097/PPO.0b013e3181c51efa. Cancer J. 2009. PMID: 20010164 Review.
Genomic analysis of high-risk smoldering multiple myeloma.
López-Corral L, Mateos MV, Corchete LA, Sarasquete ME, de la Rubia J, de Arriba F, Lahuerta JJ, García-Sanz R, San Miguel JF, Gutiérrez NC. López-Corral L, et al. Among authors: mateos mv. Haematologica. 2012 Sep;97(9):1439-43. doi: 10.3324/haematol.2011.060780. Epub 2012 Feb 13. Haematologica. 2012. PMID: 22331267 Free PMC article. Clinical Trial.
504 results